Suomi - suomi - Fimea (Suomen lääkevirasto)

accord healthcare b.v. accord healthcare b.v. - tolterodini tartras - depotkapseli, kova - 4 mg - tolterodiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

laboratoire aguettant - atropine sulfate monohydrate - injektioneste, liuos, esitäytetty ruisku - 0.2 mg/ml - atropiini

Suomi - suomi - Fimea (Suomen lääkevirasto)

huvepharma nv - eimeria necatrix, strain mednec 3+8, eimeria brunetti, strain roybru 3+28 - suspensio oraalisuspensiota varten - kokkidirokote

Suomi - suomi - Fimea (Suomen lääkevirasto)

huvepharma nv - eimeria maxima, strain mck+10, eimeria acervulina, strain ra3+20, eimeria tenella, strain rt 3+15, eimeria mitis, strain jormit 3+9 - suspensio oraalisuspensiota varten - kokkidirokote

Suomi - suomi - Fimea (Suomen lääkevirasto)

chanelle pharmaceuticals manufacturing limited - toltrazuril - oraalisuspensio - 50 mg/ml - toltratsuriili

Euroopan unioni - suomi - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Suomi - suomi - Fimea (Suomen lääkevirasto)

cp-pharma handelsgesellschaft mbh - pimobendan - purutabletti - 1.25 mg - pimobendaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

cp-pharma handelsgesellschaft mbh - pimobendan - purutabletti - 2.5 mg - pimobendaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

cp-pharma handelsgesellschaft mbh - pimobendan - purutabletti - 5 mg - pimobendaani

Suomi - suomi - Fimea (Suomen lääkevirasto)

cp-pharma handelsgesellschaft mbh - pimobendan - purutabletti - 10 mg - pimobendaani